Climb Bio, Inc. cash flow to debt ratio of -10.05K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Climb Bio, Inc.'s free cash flow has decreased 250.48% from $-15.56M last year to $-54.54M, signaling decreasing performance

Climb Bio, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Climb Bio, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Climb Bio, Inc. has a net cash position, so leverage is healthy.

Climb Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Climb Bio, Inc. has insufficient data to evaluate this check.

Climb Bio, Inc.'s short-term assets of $105.85M exceed its short-term liabilities of $6.98M

Climb Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Climb Bio, Inc.'s return on equity of -31.79%, is lower than 15.00%, indicating bad performance

Climb Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Climb Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Climb Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Climb Bio, Inc. has negative free cash flow, indicating cash burn

Climb Bio, Inc.'s yearly earnings has increased -19.01% since last year from $-73.90M to $-59.85M, signaling increasing performance

Climb Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -26.89% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Climb Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Climb Bio, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Climb Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Climb Bio, Inc. has insufficient data to evaluate this check.

Climb Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Climb Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Climb Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Climb Bio, Inc. has insufficient data to evaluate this check.

Climb Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Climb Bio, Inc. has a price-to-book ratio of 4.30x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Climb Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue